CARDIOPROTECTIVE EFFECT OF THE ANGIOTENSIN-II TYPE-1 RECEPTOR ANTAGONIST TCV-116 ON ISCHEMIA-REPERFUSION INJURY

被引：78

作者：

YOSHIYAMA, M ^{[1
]}

KIM, SK ^{[1
]}

YAMAGISHI, H ^{[1
]}

OMURA, T ^{[1
]}

TANI, T ^{[1
]}

YANAGI, S ^{[1
]}

TODA, I ^{[1
]}

TERAGAKI, M ^{[1
]}

AKIOKA, K ^{[1
]}

TAKEUCHI, K ^{[1
]}

TAKEDA, T ^{[1
]}

机构：

[1] OSAKA CITY UNIV,SCH MED,DEPT PHARMACOL,OSAKA 545,JAPAN

来源：

AMERICAN HEART JOURNAL | 1994年 / 128卷 / 01期

关键词：

D O I：

10.1016/0002-8703(94)90002-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the protective effect of angiotensin H (Ang II) type 1 receptor antagonist on myocardial ischemia-reperfusion injury and the role of exogenous Ang II to this injury in perfused hearts. We orally administered TCV-116 (Ang II type 1 receptor antagonist) and delapril (angiotesin converting enzyme inhibitor) to Wistar rats for 1 week and measured the. immunoreactive cardiac Ang II. Immunoreactive cardiac Ang II (pg/gm tissue) was 14.3 +/- 2.0 in control group, 11.8 +/- 0.8 in TCV-116-treated group, and 7.3 +/- 0.6 in delapril-treated group (p < 0.05 compared to TCV-116-treated group; p < 0.01 compared to control group). The 15 hearts (five rats in each group) were perfused by a Langendorff method and global ischemia was maintained for 30 min. Both TCV-116 and delapril were found to improve postischemic cardiac function and decrease reperfusion creatine kinase (CK) release. Ang II injection before ischemia worsened postischemic cardiac function and increased reperfusion CK release. Only TCV-116 prevented this injury. These data indicated that TCV-116 Ang II type 1 receptor antagonist was effective against myocardial ischemia-reperfusion injury, and exogenous Ang II accerelated this injury through Ang II type 1 receptor.

引用

页码：1 / 6

页数：6

共 42 条

[1] ENHANCED PROSTAGLANDIN PRODUCTION IN THE ISCHEMIC-REPERFUSED MYOCARDIUM BY CAPTOPRIL LINKED WITH ITS FREE-RADICAL SCAVENGING ACTION [J].

BAGCHI, D ;

IYENGAR, J ;

STOCKWELL, P ;

DAS, DK .

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1989, 38 (02) :145-150

[2] ISOPROTERENOL-INDUCED MYOCARDIAL FIBROSIS IN RELATION TO MYOCYTE NECROSIS [J].

BENJAMIN, IJ ;

JALIL, JE ;

TAN, LB ;

CHO, K ;

WEBER, KT ;

CLARK, WA .

CIRCULATION RESEARCH, 1989, 65 (03) :657-670

[3] EFFECTS OF 4 ANGIOTENSIN-I CONVERTING ENZYME-INHIBITORS ON REGIONAL MYOCARDIAL BLOOD-FLOW AND ISCHEMIC-INJURY DURING CORONARY-ARTERY OCCLUSION IN DOGS [J].

BERDEAUX, A ;

BONHENRY, C ;

GIUDICELLI, JF .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1987, 1 (03) :201-212

[4]

BERRIDGE MJ, 1989, JAMA-J AM MED ASSOC, V262, P1834

[5]

BHAN RD, 1982, AM J PATHOL, V108, P60

[6]

BLOOM S, 1969, AM J PATHOL, V54, P373

[7] DIFFERENTIATION OF NEUROGENIC AND MYOCARDIAL ANGIOTENSIN-11 RECEPTORS IN ISOLATED RABBIT ATRIA [J].

BLUMBERG, AL ;

ACKERLY, JA ;

PEACH, MJ .

CIRCULATION RESEARCH, 1975, 36 (06) :719-726

[8] ANGIOTENSIN RECEPTORS ARE IMPLICATED IN THE MECHANISM OF MAS ACTION [J].

BROWN, K .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (03) :87-89

[9]

DANIELL HB, 1984, J CARDIOVASC PHARM, V6, P1043

[10] ANGIOTENSIN CONVERTING ENZYME-INHIBITORS AND ISCHEMIC HEART-DISEASE [J].

ERTL, G .

EUROPEAN HEART JOURNAL, 1988, 9 (07) :716-727

← 1 2 3 4 5 →